NCT06236165View on ClinicalTrials.gov

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Hepatic and Post Hepatic Jaundice
Interventions
DRUG

N-acetylcysteine

Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.

Trial Locations (1)

31111

Faculty of Pharmacy, Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06236165 - Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice | Biotech Hunter | Biotech Hunter